BTG acquires PneumRx for up to $475 million

Thursday, December 4, 2014

London-based BTG will acquire PneumRx, a Mountain View, Calif.-based interventional pulmonology company in a deal worth up to $475 million, based on an initial consideration of $230 million and up to $245 million in performance-related milestone payments. BTG is an international specialist healthcare company active in interventional medicine and specialty pharmaceuticals. 

[Read More]